- Home
- EYEN vs ZVSA Comparison
EYEN vs ZVSA Comparison
Compare EYEN & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- ZVSA
- Stock Information
- Founded
- EYEN 2014
- ZVSA 2014
- Country
- EYEN United States
- ZVSA United States
- Employees
- EYEN N/A
- ZVSA N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- ZVSA Health Care
- Exchange
- EYEN Nasdaq
- ZVSA Nasdaq
- Market Cap
- EYEN 2.9M
- ZVSA 3.0M
- IPO Year
- EYEN 2018
- ZVSA N/A
- Fundamental
- Price
- EYEN $11.93
- ZVSA $0.69
- Analyst Decision
- EYEN Hold
- ZVSA
- Analyst Count
- EYEN 4
- ZVSA 0
- Target Price
- EYEN $2.00
- ZVSA N/A
- AVG Volume (30 Days)
- EYEN 9.8M
- ZVSA 1.5M
- Earning Date
- EYEN 08-11-2025
- ZVSA 08-08-2025
- Dividend Yield
- EYEN N/A
- ZVSA N/A
- EPS Growth
- EYEN N/A
- ZVSA N/A
- EPS
- EYEN N/A
- ZVSA N/A
- Revenue
- EYEN $67,063.00
- ZVSA N/A
- Revenue This Year
- EYEN $7,680.45
- ZVSA N/A
- Revenue Next Year
- EYEN $315.38
- ZVSA N/A
- P/E Ratio
- EYEN N/A
- ZVSA N/A
- Revenue Growth
- EYEN 663.82
- ZVSA N/A
- 52 Week Low
- EYEN $0.85
- ZVSA $0.47
- 52 Week High
- EYEN $124.80
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- EYEN 69.20
- ZVSA 53.43
- Support Level
- EYEN $3.68
- ZVSA $0.61
- Resistance Level
- EYEN $11.40
- ZVSA $0.73
- Average True Range (ATR)
- EYEN 2.03
- ZVSA 0.07
- MACD
- EYEN 0.58
- ZVSA 0.00
- Stochastic Oscillator
- EYEN 73.25
- ZVSA 36.53
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.